OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
+10.41%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$571M
AUM Growth
+$571M
(-4.7%)
Cap. Flow
-$25.5M
Cap. Flow
% of AUM
-4.46%
Top 10 Holdings %
Top 10 Hldgs %
76.16%
Holding
50
New
6
Increased
12
Reduced
12
Closed
11
Top Buys
| 1 |
Immunome
IMNM
|
$8.52M |
| 2 |
Arvinas
ARVN
|
$7.66M |
| 3 |
ESSA Pharma
EPIX
|
$3.96M |
| 4 |
Ginkgo Bioworks
DNA
|
$3.73M |
| 5 |
CRGX
CARGO Therapeutics
CRGX
|
$3.01M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23M |
| 2 |
Applied Therapeutics
APLT
|
$11.2M |
| 3 |
Ocular Therapeutix
OCUL
|
$5.83M |
| 4 |
Cytokinetics
CYTK
|
$3.98M |
| 5 |
Catalyst Pharmaceutical
CPRX
|
$2.24M |
Sector Composition
| 1 | Healthcare | 98.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
ESSA Pharma
EPIX
$11.2M
| $3.96M | 0.69% |
+2,209,998
| New | +$3.96M |
|
27
AbCellera Biologics
ABCL
$1.19B
| $2.83M | 0.49% |
965,000
+165,000
| +21% | +$483K |
|
28
UroGen Pharma
URGN
$896M
| $2.34M | 0.41% |
220,000
-184,100
| -46% | -$1.96M |
|
29
Rezolute
RZLT
$630M
| $2.28M | 0.4% |
465,000
-1,563
| -0.3% | -$7.66K |
|
30
Immatics
IMTX
$662M
| $1.17M | 0.21% |
+165,000
| New | +$1.17M |
|
31
iBio
IBIO
$16.9M
| $919K | 0.16% |
375,000
| – | – |
|
32
Lexeo Therapeutics
LXEO
$266M
| $855K | 0.15% |
+130,000
| New | +$855K |
|
33
Regenxbio
RGNX
$498M
| $618K | 0.11% |
+80,000
| New | +$618K |
|
34
Ventyx Biosciences
VTYX
$184M
| $613K | 0.11% |
+280,000
| New | +$613K |
|
35
PepGen
PEPG
$39M
| $417K | 0.07% |
110,000
-69,200
| -39% | -$262K |
|
36
Stoke Therapeutics
STOK
$1.08B
| $276K | 0.05% |
+25,000
| New | +$276K |
|
|
ADGM
37
Adagio Medical Holdings, Inc Common Stock
ADGM
$25.2M
| $116K | 0.02% |
110,571
| – | – |
|
|
RVNC
38
DELISTED
Revance Therapeutics, Inc.
RVNC
| – | – |
-275,000
| Closed | -$1.43M |
|
|
SYRS
39
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| – | – |
-654,943
| Closed | -$1.41M |
|
40
Relmada Therapeutics
RLMD
$48.8M
| – | – |
-480,000
| Closed | -$1.56M |
|
|
RGLS
41
DELISTED
Regulus Therapeutics
RGLS
| – | – |
-535,000
| Closed | -$840K |
|
42
Lyell Immunopharma
LYEL
$220M
| – | – |
-1,395,000
| Closed | -$1.93M |
|
|
43
Keros Therapeutics
KROS
$640M
| – | – |
-395,276
| Closed | -$23M |
|
|
44
Cytokinetics
CYTK
$5.98B
| – | – |
-75,300
| Closed | -$3.98M |
|
|
45
Catalyst Pharmaceutical
CPRX
$2.42B
| – | – |
-112,500
| Closed | -$2.24M |
|
|
JBIO
46
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| – | – |
-440,000
| Closed | -$920K |
|
|
ALLK
47
DELISTED
Allakos
ALLK
| – | – |
-2,407,600
| Closed | -$1.57M |
|
|
48
Applied Therapeutics
APLT
$73.7M
| – | – |
-1,320,000
| Closed | -$11.2M |
|